Crohn's Disease
A chronic inflammatory disease that can affect any part of the GI tract — from the mouth to the anus. FMT is being studied as a component of comprehensive therapy to control inflammation.
What is Crohn's disease?
Crohn's disease is a chronic inflammatory bowel disease (IBD) that affects the full thickness of the GI tract wall.
About the condition
Unlike ulcerative colitis, Crohn's disease can affect any part of the digestive tract, most commonly the terminal ileum and the beginning of the colon. The inflammation involves all layers of the intestinal wall.
Symptoms
- Chronic diarrhea
- Abdominal pain, especially in the right lower quadrant
- Weight loss, nutritional deficiencies
- Fatigue, fever
- Complications: fistulas, strictures, abscesses
Key features
- Lesions can be "skip" pattern (healthy areas between affected segments)
- Inflammation involves the full wall thickness (transmural)
- May be accompanied by extraintestinal manifestations
- Dysbiosis is an important component of pathogenesis
Standard treatment
Treatment includes corticosteroids, immunosuppressants, and biologic agents (anti-TNF, vedolizumab, ustekinumab).
Up to 50% of patients do not respond to biologic therapy or lose response over time. Many require surgery.
The role of FMT in Crohn's disease
Dysbiosis is a key factor in the development of Crohn's disease. FMT can help restore microbial balance.
Dysbiosis
Predominance of pathogenic bacteria
Barrier disruption
Antigens penetrate the intestinal wall
FMT intervention
Restoration of healthy microbiota
Inflammation control
Improved symptoms and quality of life
Mechanism of action
Healthy microbiota reduces pro-inflammatory bacteria, strengthens the intestinal barrier, modulates the immune response, and competes with pathogens for resources.
Potential benefits
- Complement to existing therapy
- Reduced frequency of flares
- Improved overall well-being
- Potential to lower medication doses
Current state of research
FMT for Crohn's disease is being actively studied. Results are encouraging, but more data is needed to standardize protocols.
20–40%
Clinical response in studies
10+
Clinical trials conducted
510
IBD patients in the Han's United cohort
IBD
Specialized journals
Key studies
- Sokol et al., Microbiome 2020: Pilot RCT: FMT showed a trend toward improvement in Crohn's disease
- Systematic reviews: FMT is safe and promising for IBD, but requires protocol optimization
- Han's United: Crohn's disease falls under the IBD category (510 patients, 64.3% overall improvement). Separate Crohn's-specific statistics are not yet available — data collection is ongoing
¥28,400 vs $17,500 for VOWST in USA
Free consultation · We respond within 24 hours
Patient story
Experience with comprehensive Crohn's disease therapy including FMT
"I've had Crohn's disease since I was 27. I tried many medications, including biologic therapy. At Han's United, they suggested adding FMT to my main treatment. I noticed improvement: less pain, more energy, fewer flares. It's not a magic pill, but it's an important part of my comprehensive therapy."
Wang M.
35 years old, Hangzhou
* Name changed. Results are individual and may vary.
Related conditions
FMT is also being studied for other GI conditions
Ulcerative Colitis
510 Han's United patients, 64.3% improvement at 3 months. Active clinical trials.
IBS
1,940 Han's United patients, 70.6% improvement at 3 months.
Functional GI
8,258 constipation patients — 70.3% improvement. Largest group in the Han's United cohort.
Chronic Diarrhea
1,730 Han's United patients, 81.0% improvement at 3 months and 72.3% at 3 years.
Related Articles
Discuss your treatment options
If you are looking for additional ways to manage Crohn's disease, schedule a consultation. A doctor will assess whether FMT could be beneficial in your case.
Free consultation · We respond within 24 hours
China, Jiangxi Province, Shangrao City, Guangxin District, West Binjiang Road